SCHEMBL4729756

SCHEMBL4729756

COc1cc(NC(C)CCCNC(=O)[C@@H](N)CCCCN)c2nc(C(C)(C)C)ccc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.49
CASP1 P29466 2/20 0.49
CYP1A2 P05177 2/20 0.49
ALDH1A1 P00352 2/20 0.49
TP53 P04637 2/20 0.49
THRB P10828 1/20 0.49
RAD52 P43351 1/20 0.49
CASP7 P55210 1/20 0.49
CASP6 P55212 1/20 0.49
CASP8 Q14790 1/20 0.49
ABCB11 O95342 1/20 0.49
ESR1 P03372 1/20 0.49
PGR P06401 1/20 0.49
ADRB2 P07550 1/20 0.49
CHRM2 P08172 1/20 0.49
ADRB1 P08588 1/20 0.49
HTR1A P08908 1/20 0.49
ADRA2A P08913 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
NQO2 P16083 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5086556 0.97 KDM4E (0.52) KDM4ECASP1CYP1A2ALDH1A1TP53
SCHEMBL6280393 0.90 HSP90AA1 (0.48) KDM4ECASP1CYP1A2ALDH1A1TP53
SCHEMBL4727368 0.90 HSP90AA1 (0.48) KDM4ECASP1CYP1A2ALDH1A1TP53
SCHEMBL6280385 0.90 HSP90AA1 (0.48) KDM4ECASP1CYP1A2ALDH1A1TP53
SCHEMBL5086470 0.88 HSP90AA1 (0.46) KDM4ECASP1CYP1A2ALDH1A1TP53
SCHEMBL4727369 0.86 KDM4E (0.48) KDM4ECASP1CYP1A2ALDH1A1TP53
SCHEMBL5080647 0.85 MAOA (0.66) KDM4ECASP1CYP1A2ALDH1A1TP53
SCHEMBL6268435 0.81 KDM4E (0.47) KDM4ECASP1CYP1A2ALDH1A1TP53
SCHEMBL6276764 0.79 KDM4E (0.46) KDM4ECASP1CYP1A2ALDH1A1TP53
SCHEMBL5086463 0.79 HSP90AA1 (0.51) KDM4ECASP1CYP1A2ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008021210-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS COMBINATORX, INCORPORATED (US) 2008-02-21 WO disclosed
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 US disclosed
US-6979740-B2 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) 2005-12-27 US disclosed
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents QDPR, SLC11A2, CYP2C8 KDM4E 64/4885CASP1 343/4885CYP1A2 66/4885
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN KDM4E 3242/4885CASP1 1680/4885CYP1A2 4587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.